<!DOCTYPE html>

<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Next-Gen Patient Avatar & AI Predictive Models</title>
    <link href="https://cdn.jsdelivr.net/npm/tailwindcss@2.2.19/dist/tailwind.min.css" rel="stylesheet">
    <style>
        body {
            background: linear-gradient(145deg, #0f172a, #1e293b);
            color: #e2e8f0;
        }
        .glass {
            background: rgba(255, 255, 255, 0.05);
            backdrop-filter: blur(10px);
            border: 1px solid rgba(255, 255, 255, 0.1);
        }
        .tech-border {
            border-image: linear-gradient(90deg, #06b6d4, #8b5cf6) 1;
            border-width: 2px;
            border-style: solid;
        }
    </style>
</head>

<body class="font-sans leading-normal tracking-normal">

    <!-- Header -->
    <header class="bg-gradient-to-r from-cyan-700 to-purple-800 text-white shadow-lg">
        <nav class="container mx-auto px-6 py-4 flex justify-between items-center">
            <img src="images/logo-white.png" alt="aiPTO Logo" class="h-10">
            <ul class="flex">
                <li class="mx-3"><a href="#" class="hover:text-cyan-200">Home</a></li>
                <li class="mx-3"><a href="#about" class="hover:text-cyan-200">About</a></li>
                <li class="mx-3"><a href="#news" class="hover:text-cyan-200">News</a></li>
                <li class="mx-3"><a href="#contact" class="hover:text-cyan-200">Contact</a></li>
            </ul>
        </nav>
    </header>

    <!-- Hero Section -->
    <section class="text-center py-20">
        <div class="container mx-auto">
            <h2 class="text-5xl font-bold text-white">Revolutionize Brain Cancer Therapy</h2>
            <p class="mt-6 text-xl text-blue-200 max-w-2xl mx-auto">Merging AI and biology to create personalized avatars and next-generation therapeutic predictions.</p>
        </div>
    </section>

    
<!-- About Section -->
<section id="about" class="relative py-20">
    <!-- Background image with 50% opacity -->
    <div class="absolute inset-0 opacity-50">
        <img src="images/IPTO.jpg" alt="Background IPTO" class="w-full h-full object-cover">
    </div>

    <!-- Text content layer -->
    <div class="relative container mx-auto px-6">
        <div class="glass p-8 rounded-lg shadow-xl">
            <h3 class="text-3xl font-bold mb-6 text-cyan-300">About</h3>

            <p class="text-blue-100 mb-6">
                aiPTO harnesses cutting-edge artificial intelligence and biomimetic modeling to replicate tumor microenvironments at a molecular level. These digital twins enable rapid prediction of patient-specific treatment responses, unlocking personalized therapeutic design and real-time drug resistance solutions.
            </p>

            <p class="text-sm text-blue-400 mt-4 text-center">Microphotography of an IPTO: the brain organoid grown from pluripotent stem cells is shown in green, the cells of the mini-tumor are stained red. Source: Liu/DKFZ.</p>

            <p class="text-blue-100 mt-10 mb-6">
                Our proprietary generative AI models analyze vast multi-omics datasets, clinical histories, and organoid phenotypes to uncover hidden patterns in disease mechanisms. By simulating therapeutic responses and disease progression, these models dramatically accelerate drug development and enable adaptive clinical strategies.
            </p>
            <img src="images/AI_engine.jpg" alt="Generative AI for Drug Discovery" class="rounded-xl shadow-2xl border-4 border-purple-500 mx-auto max-w-sm">

            <p class="text-sm text-blue-400 mt-4 text-center">Illustration of aiPTO’s generative AI engine simulating disease and treatment trajectories. Source: aiPTO Labs.</p>

            <p class="text-blue-100 mt-10 mb-6">
                By integrating patient avatars with predictive AI, aiPTO creates a powerful platform that tailors brain cancer therapy to the unique biology of each patient. This synergy redefines personalized medicine by improving drug efficacy, predicting resistance before it emerges, and reducing the time and cost of clinical development.
            </p>
            <img src="images/IPTO_AI_integration.jpg" alt="IPTO and AI Integration" class="rounded-xl shadow-2xl border-4 border-indigo-500 mx-auto max-w-sm">

            <p class="text-sm text-blue-400 mt-4 text-center">Fusion of IPTO organoid avatars with AI-based prediction pipelines for brain cancer therapy. Source: aiPTO Vision 2025.</p>
        </div>
    </div>
</section>


    <!-- News Section -->
    <section id="news" class="py-20">
        <div class="container mx-auto px-6">
            <h3 class="text-3xl font-bold mb-6 text-cyan-300">News</h3>

            <div class="glass p-6 rounded-lg">
                    <h4 class="text-xl font-semibold text-white">Breakthrough Brain Cancer Avatar Model Published</h4>
                    <p class="text-blue-200">February 2025 - aiPTO celebrates the publication of pioneering research by scientific co-founder Prof. Haikun Liu, presenting the first brain cancer avatar model capable of predicting patient responses. This patient-derived organoid platform, integrated with aiPTO's generative AI, is transforming brain cancer precision medicine and drug development. <a href="https://www.linkedin.com/posts/dkfz-de_brain-tumor-organoid-activity-7295368974081445889-6A_B?utm_source=share&utm_medium=member_desktop&rcm=ACoAAANapYsBaxKA9hpf53ivGUTGtIr2C9QuHw8" class="text-cyan-400 underline" target="_blank">View LinkedIn post</a> &nbsp;|&nbsp; <a href="https://www.dkfz.de/en/news/press-releases/detail/new-perspectives-for-personalized-therapy-of-brain-tumors" class="text-cyan-400 underline" target="_blank">Read perspectives from DKFZ</a></p>
                </div>
                
                
                <div class="glass p-6 rounded-lg">
                    <h4 class="text-xl font-semibold text-white">aiPTO Spin-Off Announced by DKFZ</h4>
                    <p class="text-blue-200">December 2024 - DKFZ officially announces the spin-off of aiPTO, a next-generation techbio startup leveraging AI and organoid technology to revolutionize brain cancer therapy. <a href="https://www.linkedin.com/posts/dkfz-innovation_innovation-cancerresearch-braincancer-activity-7274709937778241537-JtsR?utm_source=share&utm_medium=member_desktop&rcm=ACoAAANapYsBaxKA9hpf53ivGUTGtIr2C9QuHw8" class="text-cyan-400 underline" target="_blank">View LinkedIn post</a></p>
                </div>
            </div>
        </div>
    </section>

    <!-- Contact Section -->
    <section id="contact" class="py-20">
        <div class="container mx-auto px-6">
            <h3 class="text-3xl font-bold mb-6 text-cyan-300">Contact</h3>
            <div class="glass w-full max-w-lg p-6 rounded-lg mx-auto text-center">
                <p class="text-blue-100 text-lg mb-6">Send us an email at <a href="mailto:contact@aiptobio.com" class="text-cyan-400 underline">contact@aiptobio.com</a></p>
            </div>
        </div>
    </section>

    <!-- Footer -->
    <footer class="bg-gray-900 text-blue-300 text-center py-4">
        <p>© 2025 aiPTO Solutions. Empowering the future of medicine.</p>
    </footer>

</body>
</html>
